vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $83.5M, roughly 1.2× BillionToOne, Inc.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs 6.8%, a 19.8% gap on every dollar of revenue.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
BLLN vs OBK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $104.0M |
| Net Profit | $5.7M | $27.7M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 26.6% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | — | $103.4M | ||
| Q3 25 | $83.5M | $109.8M | ||
| Q2 25 | — | $83.5M | ||
| Q1 25 | — | $94.1M | ||
| Q4 24 | — | $78.3M | ||
| Q3 24 | $38.4M | $90.8M | ||
| Q2 24 | — | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | — | $29.5M | ||
| Q3 25 | $5.7M | $8.6M | ||
| Q2 25 | — | $14.6M | ||
| Q1 25 | — | $22.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-14.9M | $18.6M | ||
| Q2 24 | — | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 36.2% | ||
| Q3 25 | 11.5% | 10.0% | ||
| Q2 25 | — | 22.3% | ||
| Q1 25 | — | 30.4% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | -32.9% | 26.1% | ||
| Q2 24 | — | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | — | 28.5% | ||
| Q3 25 | 6.8% | 7.9% | ||
| Q2 25 | — | 17.5% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | -38.8% | 20.5% | ||
| Q2 24 | — | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | $0.10 | $0.27 | ||
| Q2 25 | — | $0.47 | ||
| Q1 25 | — | $0.71 | ||
| Q4 24 | — | $0.45 | ||
| Q3 24 | $-1.47 | $0.60 | ||
| Q2 24 | — | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | — |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $1.3B |
| Total Assets | $327.5M | $10.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $424.2M | ||
| Q3 25 | $195.2M | $626.9M | ||
| Q2 25 | — | $334.1M | ||
| Q1 25 | — | $486.2M | ||
| Q4 24 | — | $470.2M | ||
| Q3 24 | — | $321.2M | ||
| Q2 24 | — | $288.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $-239.5M | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $-242.9M | $1.1B | ||
| Q2 24 | — | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | — | $9.7B | ||
| Q3 25 | $327.5M | $9.8B | ||
| Q2 25 | — | $9.7B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | — | $9.7B | ||
| Q3 24 | — | $10.0B | ||
| Q2 24 | — | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $158.9M | ||
| Q3 25 | $13.8M | $59.3M | ||
| Q2 25 | — | $20.6M | ||
| Q1 25 | — | $35.6M | ||
| Q4 24 | — | $108.5M | ||
| Q3 24 | — | $39.6M | ||
| Q2 24 | — | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $151.1M | ||
| Q3 25 | $6.5M | $56.8M | ||
| Q2 25 | — | $19.6M | ||
| Q1 25 | — | $34.8M | ||
| Q4 24 | — | $86.4M | ||
| Q3 24 | — | $32.2M | ||
| Q2 24 | — | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 146.0% | ||
| Q3 25 | 7.7% | 51.7% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | — | 37.0% | ||
| Q4 24 | — | 110.3% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | 8.8% | 2.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 28.1% | ||
| Q3 24 | — | 8.1% | ||
| Q2 24 | — | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.38× | ||
| Q3 25 | 2.42× | 6.88× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | 7.60× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
